These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 18048092)

  • 1. A synthetic retinoid, TAC-101 (4-[3,5-bis (trimethylsilyl) benzamido] benzoic acid), plus cisplatin: potential new therapy for ovarian clear cell adenocarcinoma.
    Ezawa S; Suzuki N; Ohie S; Higashiguchi A; Hosoi F; Kitazato K; Susumu N; Aoki D
    Gynecol Oncol; 2008 Mar; 108(3):627-31. PubMed ID: 18048092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel retinoid, 4-[3,5-bis (trimethylsilyl) benzamido] benzoic acid (TAC-101), induces apoptosis of human ovarian carcinoma cells and shows potential as a new antitumor agent for clear cell adenocarcinoma.
    Suzuki N; Aoki D; Oie S; Horiuchi M; Hasegawa Y; Ezawa S; Suzuki A; Susumu N; Hosoi F; Kitazato K; Nozawa S
    Gynecol Oncol; 2004 Sep; 94(3):643-9. PubMed ID: 15350353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 4-[3,5-Bis(trimethylsilyl)benzamido] benzoic acid (TAC-101) induces apoptosis in colon cancer partially through the induction of Fas expression.
    Sako T; Nakayama Y; Minagawa N; Inoue Y; Onitsuka K; Katsuki T; Tsurudome Y; Shibao K; Hirata K; Nagata N; Ohie S; Kohno K; Itoh H
    In Vivo; 2005; 19(1):125-32. PubMed ID: 15796164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The induction of apoptosis and inhibition of AP-1 activity by TAC-101 (4-[3,5-bis(trimethylsilyl) benzamido] benzoic acid) may result in life prolonging effect in animals bearing metastasizing cancer.
    Shibata J; Murakami K; Aoyagi Y; Oie S; Hashimoto A; Suzuki K; Sano M; Wierzba TT; Yamada Y
    Anticancer Res; 2000; 20(5B):3583-90. PubMed ID: 11131666
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 4- [3,5-bis(trimethylsilyl)benzamido] benzoic acid (TAC-101) induced fas expression and activated caspase-3 and -8 in a DLD-1 colon cancer cell line.
    Inoue Y; Nakayama Y; Sako T; Minagawa N; Abe Y; Nagato M; Kadowaki K; Katsuki T; Matsumoto K; Tsurudome Y; Shibao K; Hirata K; Nagata N
    In Vivo; 2007; 21(2):381-7. PubMed ID: 17436592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cisplatin sensitivity of ovarian cancer in the histoculture drug response assay correlates to clinical response to combination chemotherapy with cisplatin, doxorubicin and cyclophosphamide.
    Ohie S; Udagawa Y; Kozu A; Komuro Y; Aoki D; Nozawa S; Moossa AR; Hoffman RM
    Anticancer Res; 2000; 20(3B):2049-54. PubMed ID: 10928150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anticancer effect of 4-[3,5-bis(trimethylsilyl)benzamido] benzoic acid (TAC-101) against A549 non-small cell lung cancer cell line is related to its anti-invasive activity.
    Shibata J; Murakami K; Wierzba K; Aoyagi Y; Hashimoto A; Sano M; Toko T; Yamada Y
    Anticancer Res; 2000; 20(5A):3169-76. PubMed ID: 11062739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PNAS-4, a novel pro-apoptotic gene, can potentiate antineoplastic effects of cisplatin.
    Yuan Z; Yan F; Wang YS; Liu HY; Gou LT; Zhao XY; Lai ST; Deng HX; Li J; Ding ZY; Xiong SQ; Kan B; Mao YQ; Chen LJ; Wei YQ; Zhao X
    Cancer Chemother Pharmacol; 2009 Dec; 65(1):13-25. PubMed ID: 19387645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of 4-[3,5-bis(trimethylsilyl)benzamido] benzoic acid (TAC-101) on the liver metastasis of colon 26-L5 carcinoma cells.
    Sakukawa R; Murakami K; Ikeda T; Yamada Y; Saiki I
    Oncol Res; 1998; 10(6):287-93. PubMed ID: 9848099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sensitization of tumor-associated endothelial cell apoptosis by the novel vascular-targeting agent ZD6126 in combination with cisplatin.
    Goto H; Yano S; Matsumori Y; Ogawa H; Blakey DC; Sone S
    Clin Cancer Res; 2004 Nov; 10(22):7671-6. PubMed ID: 15570000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The combination of chemotherapy and intraperitoneal MegaFas Ligand improves treatment of ovarian carcinoma.
    Etter AL; Bassi I; Germain S; Delaloye JF; Tschopp J; Sordat B; Dupuis M
    Gynecol Oncol; 2007 Oct; 107(1):14-21. PubMed ID: 17604087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glutathione peroxidase 3 is a candidate mechanism of anticancer drug resistance of ovarian clear cell adenocarcinoma.
    Saga Y; Ohwada M; Suzuki M; Konno R; Kigawa J; Ueno S; Mano H
    Oncol Rep; 2008 Dec; 20(6):1299-303. PubMed ID: 19020706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Batimastat, a synthetic inhibitor of matrix metalloproteinases, potentiates the antitumor activity of cisplatin in ovarian carcinoma xenografts.
    Giavazzi R; Garofalo A; Ferri C; Lucchini V; Bone EA; Chiari S; Brown PD; Nicoletti MI; Taraboletti G
    Clin Cancer Res; 1998 Apr; 4(4):985-92. PubMed ID: 9563894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Establishment and characterization of two human ovarian clear cell adenocarcinoma lines from metastatic lesions with different properties.
    Gorai I; Nakazawa T; Miyagi E; Hirahara F; Nagashima Y; Minaguchi H
    Gynecol Oncol; 1995 Apr; 57(1):33-46. PubMed ID: 7535723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthetic retinoid fenretinide is effective against a human ovarian carcinoma xenograft and potentiates cisplatin activity.
    Formelli F; Cleris L
    Cancer Res; 1993 Nov; 53(22):5374-6. PubMed ID: 8221674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant CD40 ligand therapy has significant antitumor effects on CD40-positive ovarian tumor xenografts grown in SCID mice and demonstrates an augmented effect with cisplatin.
    Ghamande S; Hylander BL; Oflazoglu E; Lele S; Fanslow W; Repasky EA
    Cancer Res; 2001 Oct; 61(20):7556-62. PubMed ID: 11606394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A potential use of a synthetic retinoid TAC-101 as an orally active agent that blocks angiogenesis in liver metastases of human stomach cancer cells.
    Oikawa T; Murakami K; Sano M; Shibata J; Wierzba K; Yamada Y
    Jpn J Cancer Res; 2001 Nov; 92(11):1225-34. PubMed ID: 11714448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HMOCC-1, a human monoclonal antibody that inhibits adhesion of ovarian cancer cells to human mesothelial cells.
    Suzuki N; Aoki D; Tamada Y; Susumu N; Orikawa K; Tsukazaki K; Sakayori M; Suzuki A; Fukuchi T; Mukai M; Kojima-Aikawa K; Ishida I; Nozawa S
    Gynecol Oncol; 2004 Nov; 95(2):290-8. PubMed ID: 15491748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protoapigenone, a novel flavonoid, inhibits ovarian cancer cell growth in vitro and in vivo.
    Chang HL; Su JH; Yeh YT; Lee YC; Chen HM; Wu YC; Yuan SS
    Cancer Lett; 2008 Aug; 267(1):85-95. PubMed ID: 18430509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced sensitivity of human ovarian carcinoma cell lines A2780 and A2780/CP to the combination of cisplatin and synthetic isothiocyanate ethyl 4-isothiocyanatobutanoate.
    Bodo J; Chovancova J; Hunakova L; Sedlak J
    Neoplasma; 2005; 52(6):510-6. PubMed ID: 16284698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.